Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." Cell Metabolism , 2022
Newer drugs such as tirzepatide (Mounjaro, Zepbound) target GLP1 and GIP (dual agonist)
What If You Missed a Dose
Flexible Dosing Strategy Supports Individualized Patient Response Results show that from baseline to week 68, patients in the CagriSema cohort achieved an estimated mean percent change in body weight of 20.4% compared to 3.0% in the placebo cohort (estimated difference, 17.3 percentage points
US$ 29.62
US$ 24.83
US$ 29.76
US$ 24.24
